Literature DB >> 11768291

Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data.

J P Hing1, S G Woolfrey, D Greenslade, P M Wright.   

Abstract

The purpose of this study was to examine how best to incorporate plasma samples which fall below an assay's lower limit of quantification into the process of toxicokinetic data modeling. Secondly to establish what proportion of data can be below the quantification limit without compromising NONMEM's parameter estimates. Using pharmacokinetic parameters determined in a rat toxicokinetic study we simulated datasets that might emerge from similar experiments in which only one sample was obtained per individual. A number of quantification limits were used which resulted in increasing proportions of data values being treated as if they were below the limit of quantification (BQL). For each quantification level we incorporated BQL data into our analyses in number of ways. We compared these analysis methods with respect to how well the underlying parameter values were retrieved. Omitting BQL data values or entering them as zero led to inaccurate and biased study results. We found that incorporating BQL values using more complex substitution methods via a mixed effects model produced more reliable and less biased parameter estimates. The four substitution methods that we investigated performed similarly. Parameter estimates became less reliable and more biased as the quantification level was increased depending on the method of BQL value incorporation. Naive methods of BQL data handling can produce unreliable and biased parameter estimates. An alternative is to incorporate BQL values into a population-type model, our results showed this method to be preferable. We found it advisable that the proportion of BQL data should not exceed one third and, if possible should be less than one quarter.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11768291     DOI: 10.1023/a:1012247131190

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  4 in total

1.  The Bayesian analysis of a pivotal pharmacokinetic study.

Authors:  N J Rahman; J C Wakefield; D A Stephens; C Falcoz
Journal:  Stat Methods Med Res       Date:  1999-09       Impact factor: 3.021

Review 2.  Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials.

Authors:  M D Hughes
Journal:  Stat Med       Date:  2000-12-15       Impact factor: 2.373

3.  Is mixed effects modeling or naïve pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data?

Authors:  J P Hing; S G Woolfrey; D Greenslade; P M Wright
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

4.  Analysis of animal pharmacokinetic data: performance of the one point per animal design.

Authors:  E I Ette; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1995-12
  4 in total
  17 in total

1.  Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.

Authors:  Vincent Duval; Mats O Karlsson
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

2.  Impact of censoring data below an arbitrary quantification limit on structural model misspecification.

Authors:  Wonkyung Byon; Courtney V Fletcher; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-26       Impact factor: 2.745

3.  Handling data below the limit of quantification in mixed effect models.

Authors:  Martin Bergstrand; Mats O Karlsson
Journal:  AAPS J       Date:  2009-05-19       Impact factor: 4.009

4.  Likelihood based approaches to handling data below the quantification limit using NONMEM VI.

Authors:  Jae Eun Ahn; Mats O Karlsson; Adrian Dunne; Thomas M Ludden
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-08-07       Impact factor: 2.745

5.  Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.

Authors:  Jun Shen; Angel M Carcaboso; K Elaine Hubbard; Michael Tagen; Henry G Wynn; John C Panetta; Christopher M Waters; Mohamed A Elmeliegy; Clinton F Stewart
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

6.  Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models.

Authors:  Xu Steven Xu; Adrian Dunne; Holly Kimko; Partha Nandy; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-05-31       Impact factor: 2.745

7.  Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.

Authors:  Thi Huyen Tram Nguyen; Emmanuelle Comets; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-11       Impact factor: 2.745

8.  Prophylactic ranitidine treatment in critically ill children--a population pharmacokinetic study.

Authors:  Ahmed F Hawwa; Paul M Westwood; Paul S Collier; Jeffrey S Millership; Shirish Yakkundi; Gillian Thurley; Mike D Shields; Anthony J Nunn; Henry L Halliday; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

9.  Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.

Authors:  Markos Leggas; Masashi Adachi; George L Scheffer; Daxi Sun; Peter Wielinga; Guoqing Du; Kelly E Mercer; Yanli Zhuang; John C Panetta; Brad Johnston; Rik J Scheper; Clinton F Stewart; John D Schuetz
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

Review 10.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.